Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Relling, MV, Schwab, M, Whirl-Carrillo, M, Suarez-Kurtz, G, Pui, C-H, Stein, CM, Moyer, AM, Evans, WE, Klein, TE, Antillon-Klussmann, FG, Caudle, KE, Kato, M, Yeoh, AEJ, Schmiegelow, K & Yang, JJ 2019, 'Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update', Clinical Pharmacology and Therapeutics, bind 105, nr. 5, s. 1095-1105. https://doi.org/10.1002/cpt.1304

APA

Relling, M. V., Schwab, M., Whirl-Carrillo, M., Suarez-Kurtz, G., Pui, C-H., Stein, C. M., Moyer, A. M., Evans, W. E., Klein, T. E., Antillon-Klussmann, F. G., Caudle, K. E., Kato, M., Yeoh, A. E. J., Schmiegelow, K., & Yang, J. J. (2019). Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clinical Pharmacology and Therapeutics, 105(5), 1095-1105. https://doi.org/10.1002/cpt.1304

CBE

Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui C-H, Stein CM, Moyer AM, Evans WE, Klein TE, Antillon-Klussmann FG, Caudle KE, Kato M, Yeoh AEJ, Schmiegelow K, Yang JJ. 2019. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clinical Pharmacology and Therapeutics. 105(5):1095-1105. https://doi.org/10.1002/cpt.1304

MLA

Vancouver

Author

Relling, Mary V ; Schwab, Matthias ; Whirl-Carrillo, Michelle ; Suarez-Kurtz, Guilherme ; Pui, Ching-Hon ; Stein, Charles M ; Moyer, Ann M ; Evans, William E ; Klein, Teri E ; Antillon-Klussmann, Federico Guillermo ; Caudle, Kelly E ; Kato, Motohiro ; Yeoh, Allen E J ; Schmiegelow, Kjeld ; Yang, Jun J. / Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes : 2018 Update. I: Clinical Pharmacology and Therapeutics. 2019 ; Bind 105, Nr. 5. s. 1095-1105.

Bibtex

@article{7fd81f73cacc4702a7bf035e8f317c9a,
title = "Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update",
abstract = "Thiopurine methyltransferase (TPMT) activity exhibits a monogenic codominant inheritance and catabolizes thiopurines. TPMT variant alleles are associated with low enzyme activity and pronounced pharmacologic effects of thiopurines. Loss-of-function alleles in the NUDT15 gene are common in Asians and Hispanics and reduce the degradation of active thiopurine nucleotide metabolites, also predisposing to myelosuppression. We provide recommendations for adjusting starting doses of azathioprine, mercaptopurine, and thioguanine based on TPMT and NUDT15 genotypes (updates on www.cpicpgx.org).",
author = "Relling, {Mary V} and Matthias Schwab and Michelle Whirl-Carrillo and Guilherme Suarez-Kurtz and Ching-Hon Pui and Stein, {Charles M} and Moyer, {Ann M} and Evans, {William E} and Klein, {Teri E} and Antillon-Klussmann, {Federico Guillermo} and Caudle, {Kelly E} and Motohiro Kato and Yeoh, {Allen E J} and Kjeld Schmiegelow and Yang, {Jun J}",
note = "{\textcopyright} 2018 The Authors Clinical Pharmacology & Therapeutics {\textcopyright} 2018 American Society for Clinical Pharmacology and Therapeutics.",
year = "2019",
doi = "10.1002/cpt.1304",
language = "English",
volume = "105",
pages = "1095--1105",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

RIS

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes

T2 - 2018 Update

AU - Relling, Mary V

AU - Schwab, Matthias

AU - Whirl-Carrillo, Michelle

AU - Suarez-Kurtz, Guilherme

AU - Pui, Ching-Hon

AU - Stein, Charles M

AU - Moyer, Ann M

AU - Evans, William E

AU - Klein, Teri E

AU - Antillon-Klussmann, Federico Guillermo

AU - Caudle, Kelly E

AU - Kato, Motohiro

AU - Yeoh, Allen E J

AU - Schmiegelow, Kjeld

AU - Yang, Jun J

N1 - © 2018 The Authors Clinical Pharmacology & Therapeutics © 2018 American Society for Clinical Pharmacology and Therapeutics.

PY - 2019

Y1 - 2019

N2 - Thiopurine methyltransferase (TPMT) activity exhibits a monogenic codominant inheritance and catabolizes thiopurines. TPMT variant alleles are associated with low enzyme activity and pronounced pharmacologic effects of thiopurines. Loss-of-function alleles in the NUDT15 gene are common in Asians and Hispanics and reduce the degradation of active thiopurine nucleotide metabolites, also predisposing to myelosuppression. We provide recommendations for adjusting starting doses of azathioprine, mercaptopurine, and thioguanine based on TPMT and NUDT15 genotypes (updates on www.cpicpgx.org).

AB - Thiopurine methyltransferase (TPMT) activity exhibits a monogenic codominant inheritance and catabolizes thiopurines. TPMT variant alleles are associated with low enzyme activity and pronounced pharmacologic effects of thiopurines. Loss-of-function alleles in the NUDT15 gene are common in Asians and Hispanics and reduce the degradation of active thiopurine nucleotide metabolites, also predisposing to myelosuppression. We provide recommendations for adjusting starting doses of azathioprine, mercaptopurine, and thioguanine based on TPMT and NUDT15 genotypes (updates on www.cpicpgx.org).

U2 - 10.1002/cpt.1304

DO - 10.1002/cpt.1304

M3 - Journal article

C2 - 30447069

VL - 105

SP - 1095

EP - 1105

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -

ID: 59083943